Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract

Biochemical and Biophysical Research Communications

Volumn 318, Issue 4, 2004, Pages 1072-1078

  Gaudineau, Cédric ^a   Beckerman, Rachel ^a   Welbourn, Sarah ^a   Auclair, Karine ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Bilobalide; CYP; Flavonoids; Ginkgo biloba; Ginkgolides; Inhibition; P450; Terpenoids

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; FLAVANOID; GINKGO BILOBA EXTRACT; TERPENOID DERIVATIVE;

ARTICLE; CHROMATOGRAPHY; CONTROLLED STUDY; DRUG ISOLATION; ENZYME INHIBITION; FRACTIONATION; GINKGO BILOBA; HUMAN; HUMAN CELL; MEDICINAL PLANT; MICROSOME; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

CHEMICAL FRACTIONATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FLAVONOIDS; GINKGO BILOBA; HUMANS; ISOENZYMES; KINETICS; NADP; PLANT EXTRACTS; TERPENES;

GINKGO BILOBA;

EID: 2442534164     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.04.139     Document Type: Article

References (47)

1. Ortiz de Montellano P.R. Cytochrome P450: Structure, Mechanism, and Biochemistry. second ed. 1995;Plenum, New York
2. DeFeudis F.V. Ginkgo biloba extract (EGb761): From chemistry to the clinic. 1998;Ullstein Medical, Wiesbaden
3. Elovic E.P., Zafonte R.D. Ginkgo biloba: applications in traumatic brain injury. J. Head Trauma Rehabil. 16:2001;603-607
4. Drieu K. Préparation et définition de l'extrait de Ginkgo biloba. Presse Med. 15:1986;1455-1475
5. Cohen-Salmon C., Venault P., Martin B., Raffalli-Sébille M.J., Barkats M., Clostre F., Pardon M.C., Christen Y., Chapouthier G. Effects of Ginkgo biloba extract (EGb 761) on learning and possible actions on aging. J. Physiol. 91:1997;291-300
6. Thiagaraja G., Chandani S., Rao S.H., Samuni A.M., Chandrasekaran K., Balasubramanian D. Molecular and cellular assessment of Ginkgo biloba extract as a possible ophthalmic drug. Exp. Eye Res. 75:2002;421-430
7. Rioufol G., Pietri S., Culcasi M., Loufoua J., Staat P., Pop C., Drieu K., Ovize M. Ginkgo biloba extract EGb761 attenuates myocardial stunning in the pig heart. Basic Res. Cardiol. 98:2003;59-68
8. DeFeudis F.V. A brief history of EGb761 and its therapeutic uses. Pharmacopsychiatry. 36(Suppl. 1):2003;S2-S7
9. Gertz H.-J., Kiefer M. Review about Ginkgo biloba special extract EGb761 (Ginkgo). Curr. Pharmacol. Des. 10:2004;261-264
10. Amri H., Ogwuegbu S.O., Boujrad N., Drieu K., Papadopoulos V. In vivo regulation of the peripheral-type benzodiazepine receptor and glucocorticoid synthesis by the Ginkgo biloba extract EGb761 and isolated ginkgolides. Endocrinology. 137:1996;5707-5718
11. Porsolt R.D., Martin P., Lenegre A., Fromage S., Drieu K. Effects of an extract of Ginkgo biloba on "learned helplessness" and other models of stress in rodents. Pharmacol. Biochem. Behav. 36:1990;963-971
12. Rapin J.R., Lamproglou I., Drieu K., DeFeudis F.V. Demonstration of the "anti-stress" activity of an extract of Ginkgo biloba using a discrimination learning task. Gen. Pharmacol. 25:1994;1009-1016
13. Bastianetto S., Quirion R. EGb 761 is a neuroprotective agent against β-amyloid toxicity. Cell. Mol. Biol. 48:2002;693-697
14. Zhao H.W., Li X.Y. Ginkgolide A, B, and huperzine A inhibit nitric oxide-induced neurotoxicity. Int. Immunopharmacol. 2:2002;1551-1556
15. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharm. 9:1994;215-222
16. Kanowski S., Herrmann W.M., Stephan K., Wierich W., Horr R. Proof of efficacy of the Ginkgo biloba special extract EGb761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 29:1996;47-56
17. Maurer K., Ihl R., Dierks T., Frölich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J. Psychiat. Res. 31:1997;645-655
18. Gold P.E., Cahill L., Wenk G.L. The lowdown on Ginkgo biloba. Sci. Am. 288:2003;86-91
19. Luo Y., Smith J.V., Paramasivam V., Burdick A., Curry K.J., Buford J.P., Khan I., Netzer W.J., Xu H., Butko P. Inhibition of amyloid-β aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. 99:2002;12197-12202
20. Bastianetto S., Quirion R. Natural extracts as possible protective agents of brain aging. Neurobiol. Aging. 23:2002;891-897
21. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica. 32:2002;451-478
22. Sorensen J.M. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J. Altern. Compl. Med. 8:2002;293-308
23. Brazier N.C., Levine M.A.H. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am. J. Therap. 10:2003;163-169
24. Valli G., Giardina A.V. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J. Am. Coll. Cardiol. 39:2002;1083-1095
25. Budzinski J.W., Foster B.C., Vandenhoek S., Arnason J.T. An in vitro evaluation of human cytochrome CYP3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 7:2000;273-282
26. Huynh H.T., Teel R.W. Effects of plant-derived phenols on rat liver cytochrome CYP2B1 activity. Anticancer Res. 22:2003;1699-1704
27. Lautraite S., Musonda A.C., Doehmer J., Edwards G.O., Chipman J.K. Flavonoids inhibit genetic toxicity produced by carcinogens in cells expressing CYP1A2 and CYP1A1. Mutagenesis. 17:2002;45-53
28. Zou L., Harkey M.R., Henderson G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 71:2002;1579-1589
29. Ryu S.D., Chung W.G. Induction of the procarcinogen-activating CYP1A2 by a herbal dietary supplement in rats and humans. Food Chem. Toxicol. 41:2003;861-866
30. Shinozuka K., Umegaki K., Kubota Y., Tanaka N., Mizuno H., Yamauchi J., Nakamura K., Kunitomo M. Feeding Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci. 70:2002;2783-2792
31. Umegaki K., Saito K., Kubota Y., Sanada S.H., Yamada K., Shinzuka K. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn. J. Pharmacol. 90:2002;345-351
32. Kubota Y., Kabayashi K., Tanaka N., Nakamura K., Kunimoto M., Umegaki K., Shinozuka K. Interaction of Ginkgo biloba (GBE) with hypotensive agent, nicardipine, in rats. In vivo. 17:2003;409-412
33. Ohnishi N., Kusuhara M., Yoshioka M., Kuroda K., Soga A., Nishikawa F., Koshi T., Nakagawa M., Hori S., Matsumoto T., Yamashita M., Takara K., Yokoyama T. Studies on interactions between functional foods and dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extracts on the pharmacokinetics of diltiazem in rats. Biol. Pharm. Bull. 26:2003;1315-1320
34. Kuo I.F., Chen J., Chang T.K.H. Effect of Gingko biloba on rat hepatic microsomal CYP1A activity: role of gingkolides, bilobalide, and flavonols, Can. J. Physiol. Pharmacol. 82:2004;57-64
35. Raucy J.L Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug. Metab. Dispos. 31:2003;533-539
36. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry B., Cui Y., Ang C.Y.W. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Therap. 72:2003;276-286
37. Gaudineau C., Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem. Biophys. Res. Commun. 317:2004;950-956
38. Jay M., Gonnet J.-F., Wollenweber E., Voirin E. Qualitative analysis of non-glycosylated flavonoids for the purpose of chemotaxonomy (in french). Phytochemistry. 14:1975;1605-1612
39. Hasler I., Sticher O. Identification and determination of the flavonoids from Ginkgo biloba by high-performance liquid chromatography. J. Chromatogr. 605:1992;41-48
40. Chang T.K.H., Chen J., Lee W.B.K. Differential inhibition and inactivation of human P450 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Therap. 299:2001;874-882
41. Kariv I., Fereshteh M.P., Oldenburg K.R. Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome CYP2D6 and CYP3A4 metabolism. J. Biomol. Screening. 6:2001;91-99
42. Venhorst J., Rooseboom M., Vermeulen N.P.E., Commandeur J.N.M. Studies on the inhibition of human cytochromes P450 by selenocysteine Se-conjugates. Xenobiotica. 33:2003;57-72
43. Miller V.P., Stresser D.M., Blanchard A.P., Turner S., Crespi C.L. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann. N. Y. Acad. Sci. 919:2000;26-32
44. Miller G.P., Guengerich F.P. Binding and oxidation of alkyl 4-nitrophenyl ethers by rabbit cytochrome CYP1A2: evidence for two binding sites. Biochemistry. 40:2001;7262-7272
45. Tang Y., Lou F., Wang J., Li Y., Zhuang S. Coumaroyl flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry. 58:2002;1251-1256
46. Hasler A., Gross G.-A., Meier B., Sticher O. Complex flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry. 31:1992;1391-1394
47. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34:2002;83-448